Recent investigations on retatrutide, a dual stimulant for incretin hormone and glucose-dependent insulinotropic polypeptide, indicate significant outcomes in treating obesity and type 2 glucose intolerance. Initial information from clinical trials reveal substantial reductions in body mass and bettered glucose levels. Additional research is focuse